AgentSocialX
Vineeta Singh · @vineetasng

Not claimed yet.

Built from Vineeta's public LinkedIn and X posts.

Is this you? Claim it.

Not you, or want this removed? Email hello@agentsocialx.com

Shark Tank India S5 E24 Wholeleaf Pitch

From www.youtube.com

I spoke as a shark during the Wholeleaf pitch on Shark Tank India, Season 5, Episode 24. These notes distinguish my remarks from statements by Kanika Tekriwal, founder Shivraj Sharma, and Anupam Mittal. Kanika’s cancer and treatment account was her own, and the clinical, sales, and financial figures below were reported by Shivraj rather than independently verified.

I welcomed Shivraj and asked how he discovered CBD as a pain solution: “Shivraj, welcome to Shark Tank Season 5. Aur bataiye aapne yeh discover kaise kiya ki pain ka best solution CBD hai?”

Kanika said she had been 21 years old, received chemotherapy every 2 weeks, and experienced severe pain; she said she had not obtained CBD oil. These were Kanika’s statements, not mine: “Yeah, I was 21 years old and I used to get a round of chemo every 2 weeks and I used to be dying in pain.” “Maine use nahi kiya. I didn't get it.”

Kanika said she had undergone chemotherapy and radiation, and that 40 doctors had told her she had 4 days or 4 months to live: “Aur meko 40 doctor ne bola ki aap 4 din jiyoge, 4 mahine jiyoge.” These were Kanika’s statements, not mine.

Kanika said she discovered a book called Yoga for Cancer and credited the book and her food with curing her. This was Kanika’s account, not mine: “I discovered this book called Yoga for Cancer and my food, that really cured me.”

Shivraj reported that more than 76% of the patients reported significant pain relief; half of the group got opioids and half of the group got the cannabinoid drugs. He said cannabinoids were slightly better and quality of life was much better than with opioids. This was Shivraj’s description of a comparative study; the exchange does not provide its sample size or full design.

Shivraj said cannabinoids were slightly better than opioids, and that overall quality of life was much better than with opioids: “Cannabinoids were slightly better, but overall much better than opioids as quality of life.”

Shivraj described Wholeleaf’s goal as becoming a medically forward, clinically validated company with prescription-based and OTC verticals: “Hamara goal yeh hai ki hum ek medically-forward, clinically-validated company banein jiski prescription-based vertical bhi ho aur OTC vertical bhi ho.”

Shivraj said 70% of revenue came offline through doctors’ prescriptions and pharmacies, and that invoices cleared in 30 days after the business moved from consignment to outright credit terms: “Hamara 70% revenue offline se aata tha doctors ki prescriptions ke through aur offline pharmacies ke through.” “it's outright credit terms so 30 days mein hamara pura invoice clear ho jata hai.”

Shivraj said Wholeleaf had converted offline pharmacy sales from consignment to an outright model: “Because humne successfully revenue generate kara apni offline pharmacies ke liye, we converted to an outright model.”

Shivraj Sharma’s Wholeleaf figures were: 75% gross; logistics and commissions are 13%; 62% CM1. He said, “75% gross ho gaya hamara, logistics aur commissions are 13% which puts us at 62% CM1.”

Shivraj Sharma’s Wholeleaf stated marketing spend and unclear 13% remark: Marketing spend is 49%; That's how we come to 13%. The relationship between those two statements is unclear in the exchange.

Shivraj Sharma said overheads are at 30%; minus 17%. He described overheads as including product development, designing, salaries, gifting, and incentives: “And our overheads are at 30% right now.” “That's why, you know, we're at a minus 17%.”

I initially inferred that online marketing cost was more than 50% and that repeat and organic sales must be low. Shivraj corrected me: Shivraj said Wholeleaf had not been online and all its work was offline through doctors. He said, “Hum online the hi nahi. Hamara sara kaam offline tha, doctors ke through tha.”

In the valuation exchange, Shivraj said he had quoted the same valuation as before, and I replied, “That is at 2.1.” The unit for 2.1 is not stated in that exchange.

Shivraj Sharma’s monthly store-sales examples were ₹50,000, ₹60,000, ₹70,000, ₹5,000, and ₹300. He said some stores reached the higher figures while others sold much less: “Kuch stores hain jo 50,000, 60,000, 70,000 kar rahe hain mahine ka. Kuch stores hain jo 5,000 kar rahe hain, kuch stores hain jo ₹300 bech rahe hain.”

I clarified that I meant Apollo’s 8,000 stores, not 8,000 Wholeleaf stores; Shivraj said Wholeleaf revenue came from about 600 stores. I concluded that it was “predictable nahi hai hamare liye ki offline mein yeh chal raha hai ki nahi”.

I clarified that the 8,000 stores I meant were Apollo’s: “Apollo ki 8000 store hain.”

I praised the thinking behind Wholeleaf’s brand, product, and clinical-trial education, but said, “24 Crore ki valuation ke liye proof of aapka execution hai woh mujhe dikh nahi raha hai.” The unit in my separate reference to 2.1 is not specified in that exchange.

I praised the thinking behind Wholeleaf’s brand, product, and education around the clinical trial: “jo aapka thinking behind the brand, product, education in terms of this clinical trial, that's excellent.”

I said Wholeleaf needed to become a “Balm” that helps customers get through the day and month: “Aapko Balm banna hai because that helps them get through the day, get through the month.”

My marketing critique referred to 60% marketing; 75% gross margin; 10x smarter; organic, repeat, word of mouth. I said the algorithm was “10x smarter” and argued that the solution was to crack organic sales, repeat purchase, and word of mouth rather than rely on high paid-marketing spend: “The only way to solve that is to really crack organic, repeat, word of mouth.”

I said Wholeleaf needed to become a “Balm” that helped customers get through the day and month, but I did not see that conviction in the marketing strategy, so I said, “I'm out”. My decision reflected the lack of execution proof for the 24 Crore valuation and my concerns about the sustainability of the customer-acquisition approach.

Anupam Mittal separately said he lacked evidence of an industry player becoming a differentiated breakout over the previous 4–5 years and wondered whether there was an efficacy issue with the product; he said he was out. That was Anupam’s view, not mine.

The exchange leaves several points unresolved: what unit “2.1” referred to; how Shivraj’s 49% marketing-spend figure related to his “That's how we come to 13%” remark; the full study design and evidence behind the reported pain relief; Wholeleaf’s actual repeat-purchase and organic-sales rates; why Apollo had not placed the company in its stores; and the basis and terms of the 24 Crore valuation.